The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Open accessAbstract
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL). PATIENTS AND METHODS: A systematic literature review identified recent advances in the management of AIBL. Results with individual agents were assessed based on trial design, size, follow-up, and safety. RESULTS: Several fracture related risk factors in patients with EBC were identified. Although, the FRAX algorithm includes fracture risk factors (RF) in addition to BMD, it does not seem to adequately address the effects of AIBL. Several antiresorptive agents can prevent and treat AIBL. However, concerns regarding compliance and long-term safety remain. Overall, the evidence for fracture prevention is strongest for denosumab 60 mg s.c. every 6 months. Additionally, recent studies as well as an individual patient data meta-analysis of all available randomized trial data support additional anticancer benefits from adjuvant bisphosphonate treatment in postmenopausal women with a 34% relative risk reduction in bone metastasis and 17% relative risk decrease in breast cancer mortality that needs to be taken into account when advising on management of AIBL. CONCLUSIONS: In all patients initiating AI treatment, fracture risk should be assessed and recommendation with regard to exercise and calcium/vitamin D supplementation given. Bone-directed therapy should be given to all patients with a T-score<-2.0 or with a T-score of <-1.5 SD with one additional RF, or with ≥2 risk factors (without BMD) for the duration of AI treatment. Patients with T-score>-1.5 SD and no risk factors should be managed based on BMD loss during the first year and the local guidelines for postmenopausal osteoporosis. Compliance should be regularly assessed as well as BMD on treatment after 12 - 24 months. Furthermore, because of the decreased incidence of bone recurrence and breast cancer specific mortality, adjuvant bisphosphonates are recommended for all postmenopausal women at significant risk of disease recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
(1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90218-e · Cited by 2,874
Hernlund, E., Svedbom, A., Ivergård, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E. V., Jönsson, B., & Kanis, J. A. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0136-1 · Cited by 2,675
Self-citationBliuc, D. (2009) · JAMA · doi:10.1001/jama.2009.50 · Cited by 1,699
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Body mass index as a predictor of fracture risk: A meta-analysis
De Laet, C., Kanis, J. A., Odén, A., Johanson, H., Johnell, O., Delmas, P., Eisman, J. A., Kroger, H., Fujiwara, S., Garnero, P., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1863-y · Cited by 1,622
Self-citation(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,374
A meta-analysis of previous fracture and subsequent fracture risk
Kanis, J. A., Johnell, O., De Laet, C., Johansson, H., Oden, A., Delmas, P., Eisman, J., Fujiwara, S., Garnero, P., Kroger, H., et al. (2004) · Bone · doi:10.1016/j.bone.2004.03.024 · Cited by 1,278
Self-citationThe global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Exercise for preventing and treating osteoporosis in postmenopausal women
Howe, T. E., Shea, B., Dawson, L. J., Downie, F., Murray, A., Ross, C., Harbour, R. T., Caldwell, L. M., & Creed, G. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000333.pub2 · Cited by 1,083
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Self-citationSmoking and fracture risk: a meta-analysis
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., De Laet, C., Eisman, J. A., Fujiwara, S., Kroger, H., McCloskey, E. V., Mellstrom, D., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1640-3 · Cited by 999
Self-citationHillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Coates, A. S., Keshaviah, A., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, M., Gelber, R. D., Colleoni, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8617 · Cited by 910
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
Self-citationOral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Rheumatology · doi:10.1093/rheumatology/39.12.1383 · Cited by 696
Self-citationExtending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., Strasser-Weippl, K., Rubin, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604700 · Cited by 644
Alcohol intake as a risk factor for fracture
Kanis, J. A., Johansson, H., Johnell, O., Oden, A., De Laet, C., Eisman, J. A., Pols, H., & Tenenhouse, A. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1734-y · Cited by 624
Self-citationBone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocaña, A. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr242 · Cited by 622
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Self-citationGnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balic, M., Haslbauer, F., Melbinger, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60995-3 · Cited by 559
Self-citationEllis, G. K., Bone, H. G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J., Fan, M., & Jun, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3832 · Cited by 483
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Self-citationA family history of fracture and fracture risk: a meta-analysis
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., De Laet, C., Eisman, J. A., McCloskey, E. V., Mellstrom, D., Melton, L. J., Pols, H. A. P., et al. (2004) · Bone · doi:10.1016/j.bone.2004.06.017 · Cited by 434
Self-citationColeman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., Cawthorn, S. J., Patel, A., Snowdon, C. F., Hall, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70003-7 · Cited by 426
Self-citationLeslie, W. D., Rubin, M. R., Schwartz, A. V., & Kanis, J. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1759 · Cited by 352
Self-citationVan Poznak, C. H., Temin, S., Yee, G. C., Janjan, N. A., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Geoghegan, C., Hillner, B. E., Theriault, R. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5209 · Cited by 342
Coleman, R., de Boer, R., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., von Minckwitz, G., Sleeboom, H. P., Forbes, J., Barrios, C., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds277 · Cited by 339
Self-citationEidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., von Minckwitz, G., Miller, J., Schenk, N., & Coleman, R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq217 · Cited by 281
Self-citationAdherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ziller, V., Kalder, M., Albert, U.-S., Holzhauer, W., Ziller, M., Wagner, U., & Hadji, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn646 · Cited by 263
Self-citationBone Loss and Fracture Risk Associated with Cancer Therapy
Guise, T. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1121 · Cited by 239
Reid, D. M., Doughty, J., Eastell, R., Heys, S. D., Howell, A., McCloskey, E. V., Powles, T., Selby, P., & Coleman, R. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.007 · Cited by 228
Self-citationPractical guidance for the management of aromatase inhibitor-associated bone loss
Hadji, P., Body, J.-J., Aapro, M. S., Brufsky, A., Coleman, R. E., Guise, T., Lipton, A., & Tubiana-Hulin, M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn164 · Cited by 225
Self-citationPrevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial
Van Poznak, C., Hannon, R. A., Mackey, J. R., Campone, M., Apffelstaedt, J. P., Clack, G., Barlow, D., Makris, A., & Eastell, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5902 · Cited by 224
Brufsky, A. M., Bosserman, L. D., Caradonna, R. R., Haley, B. B., Jones, C. M., Moore, H. C. F., Jin, L., Warsi, G. M., Ericson, S. G., & Perez, E. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.015 · Cited by 214
Hadji, P., Coleman, R. E., Wilson, C., Powles, T. J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv617 · Cited by 207
Self-citationLester, J. E., Dodwell, D., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., Brown, J. E., Hannon, R. A., & Coleman, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5101 · Cited by 189
Self-citationOral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women
Chlebowski, R. T., Chen, Z., Cauley, J. A., Anderson, G., Rodabough, R. J., McTiernan, A., Lane, D. S., Manson, J. E., Snetselaar, L., Yasmeen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.2095 · Cited by 187
Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp033 · Cited by 186
Effects of exercise on fracture reduction in older adults: A systematic review and meta-analysis
Kemmler, W., Häberle, L., & von Stengel, S. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2248-7 · Cited by 174
Hadji, P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.013 · Cited by 165
Self-citationPopp, A. W., Zysset, P. K., & Lippuner, K. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3458-6 · Cited by 159
Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
Hadji, P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.02.001 · Cited by 152
Self-citationMiller, P. D., Wagman, R. B., Peacock, M., Lewiecki, E. M., Bolognese, M. A., Weinstein, R. L., Ding, B., Martín, J. S., & McClung, M. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1805 · Cited by 141
Díez‐Pérez, A., Naylor, K. E., Abrahamsen, B., Agnusdei, D., Brandi, M. L., Cooper, C. C., Dennison, E. M., Eriksen, E. F., Gold, D. T., Guañabens, N., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3906-6 · Cited by 141
Self-citationConfavreux, C. B., Fontana, A., Guastalla, J. P., Munoz, F., Brun, J., & Delmas, P. D. (2007) · Bone · doi:10.1016/j.bone.2007.06.004 · Cited by 127
Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
Newcomb, P. A., Trentham‐Dietz, A., & Hampton, J. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605555 · Cited by 126
Hadji, P., Claus, V., Ziller, V., Intorcia, M., Kostev, K., & Steinle, T. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1535-z · Cited by 114
Self-citationBody, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Reginster, J., Rozenberg, S., & Kaufman, J. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0439-4 · Cited by 113
Self-citationRizzoli, R., Body, J., DeCensi, A., Reginster, J., Piscitelli, P., & Brandi, M. L. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1870-0 · Cited by 110
Self-citationDirect healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures
Shi, N., Foley, K. A., Lenhart, G. M., & Badamgarav, E. (2009) · Bone · doi:10.1016/j.bone.2009.07.086 · Cited by 99
Greenspan, S. L., Brufsky, A., Lembersky, B. C., Bhattacharya, R. K., Vujevich, K. T., Perera, S., Sereika, S. M., & Vogel, V. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2967 · Cited by 94
Bock, O., & Felsenberg, D. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2134 · Cited by 93
Hines, S. L., Mincey, B. A., Dentchev, T., Sloan, J. A., Perez, E. A., Johnson, D. B., Schaefer, P., Alberts, S. R., Liu, H., Kahanic, S. P., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0332-2 · Cited by 91
Multiple clinical vertebral fractures following denosumab discontinuation
Anastasilakis, A. D., & Makras, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3459-5 · Cited by 91
Šestak, I., Singh, S., Cuzick, J. M., Blake, G. M., Patel, R., Gossiel, F., Coleman, R. E., Dowsett, M., Forbes, J., Howell, A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71035-6 · Cited by 71
Self-citationMiller, P. D. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0018-6 · Cited by 70
Hadji, P., Ziller, M., Kieback, D., Dornoff, W., Tessen, H. W., Menschik, T., Kuck, J., Melchert, F., & Hasenburg, A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn762 · Cited by 70
Self-citationColeman, R. E., Bundred, N. J., Boer, R. D., Llombarto, A., Campbell, I. D., Neven, P., Barrios, C. H., Dias, R., Miller, J. C., & Brufsky, A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-4082 · Cited by 65
Self-citationDatta, M., & Schwartz, G. G. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.002 · Cited by 61
Cancer Treatment-Induced Bone Loss in women with breast cancer
Hadji, P. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.60 · Cited by 51
Self-citationEdwards, B. J.-A., Raisch, D. W., Shankaran, V., McKoy, J. M., Gradishar, W. J., Bunta, A. D., Samaras, A. T., Boyle, S. N., Bennett, C. L., West, D. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1595 · Cited by 51
Bone health in the elderly cancer patient: A SIOG position paper
Body, J., Terpos, E., TOMBAL, B. F., Hadji, P., Arif, A., Young, A., Aapro, M., & Coleman, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.004 · Cited by 51
Self-citationSaarto, T., Vehmanen, L., Elomaa, I., Välimäki, M., Mäkelä, P. M., & BLOMQVIST, C. P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1729 · Cited by 50
Bone turnover across the menopause transition: The role of gonadal inhibins
Nicks, K. M., Fowler, T. W., Akel, N. S., Perrien, D. S., Suva, L. J., & Gaddy, D. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05349.x · Cited by 49
Oral Bisphosphonates and Improved Survival of Breast Cancer
Rennert, G., Pinchev, M., Gronich, N., Saliba, W., Flugelman, A. A., Lavi, I., Goldberg, H., Fried, G., Steiner, M., Bitterman, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0547 · Cited by 49
Greenspan, S. L., Vujevich, K. T., Brufsky, A., Lembersky, B. C., Londen, G. J. V., Jankowitz, R., Puhalla, S. L., Rastogi, P., & Perera, S. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3100-7 · Cited by 48
Adverse bone effects during pharmacological breast cancer therapy
Bjarnason, N. H., Hitz, M. F., Jørgensen, N. R., Vestergaard, P., & (on behalf of the board of Danish Bone Society) (2008) · Acta Oncologica · doi:10.1080/02841860802001467 · Cited by 45
Fracture risk in women with breast cancer: A population-based study
Melton, L. J., Hartmann, L. C., Achenbach, S. J., Atkinson, E. J., Therneau, T. M., & Khosla, S. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1556 · Cited by 45
Adherence and persistence: Impact on outcomes and health care resources
Reginster, J. (2006) · Bone · doi:10.1016/j.bone.2005.11.013 · Cited by 44
Self-citationCost of fractures commonly associated with osteoporosis in a managed-care population
Christensen, L. S., Iqbal, S. U., Macarios, D., Badamgarav, E., & Harley, C. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.488969 · Cited by 43
Hadji, P., Asmar, L., van Nes, J. G. H., Menschik, T., Hasenburg, A., Kuck, J., Nortier, J. W. R., van de Velde, C. J. �., Jones, S. E., & Ziller, M. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0964-y · Cited by 42
Self-citationCancer-associated muscle weakness: What's bone got to do with it?
Waning, D. L., & Guise, T. A. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.59 · Cited by 41
Neuner, J. M., Yen, T. W. F., Sparapani, R., Laud, P. W., & Nattinger, A. B. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1493-x · Cited by 40
Schimdt, N., Jacob, L., Coleman, R. E., Kostev, K., & Hadji, P. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3661-3 · Cited by 39
Self-citationWagner‐Johnston, N. D., Sloan, J. A., Liu, H., Kearns, A. E., Hines, S. L., Puttabasavaiah, S., Dakhil, S. R., Lafky, J. M., Perez, E. A., & Loprinzi, C. L. (2015) · Cancer · doi:10.1002/cncr.29327 · Cited by 38
Compliance and persistence with osteoporosis therapies
Silverman, S. L., & Gold, D. T. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0021-x · Cited by 38
Knobf, M. T., Jeon, S., Smith, B. A., Harris, L. N., Kerstetter, J. E., Thompson, A. S., & Insogna, K. L. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3693-3 · Cited by 38
Colzani, E., Clements, M., Johansson, A. L. V., Liljegren, A., He, W., Brand, J. S., Adolfsson, J., Fornander, T., Hall, P. N., & Czene, K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.314 · Cited by 37
Kyvernitakis, I., Rachner, T. D., Urbschat, A., Hars, O., Hofbauer, L. C., & Hadji, P. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1726-z · Cited by 34
Self-citationServitja, S., Martos, T., Rodríguez-Sanz, M., García‐Giralt, N., Prieto‐Alhambra, D., Garrigós, L., Nogués, X., & Tusquets, I. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015598536 · Cited by 34
Assessment of fracture risk in women with breast cancer using current vs emerging guidelines
Hadji, P., Ziller, M., Albert, U., & Kalder, M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605548 · Cited by 31
Self-citationLomax, A. J., Yap, S. Y., White, K. N., Beith, J. M., Abdi, E. A., Broad, A., Sewak, S., Lee, C., Sambrook, P. N., POCOCK, N. A., et al. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.08.001 · Cited by 30
Rhee, Y., Song, K., Park, S., Park, H. S., Lim, S.-K., & Park, B. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0283 · Cited by 28
Schmidt, N., Jacob, L., Coleman, R. E., Kostev, K., & Hadji, P. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3819-7 · Cited by 28
Self-citationLiver X Receptor Gene Polymorphisms in Tuberculosis: Effect on Susceptibility
Han, M. S., Liang, L., Liu, L., Yue, J., Zhao, Y., & Xiao, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095954 · Cited by 27
Lee, S. J., Kim, K. M., Brown, J. K., Brett, A., Roh, Y. H., Kang, D. R., Park, B., & Rhee, Y. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0046-x · Cited by 26
Lester, J., Dodwell, D. J., Brown, J. E., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., & Coleman, R. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.06.002 · Cited by 25
Self-citationCarbonell-Abella, C., Pagès-Castellà, A., Javaid, M. K., Nogués, X., Farmer, A. A., Cooper, C. C., Díez‐Pérez, A., & Prieto‐Alhambra, D. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0040-3 · Cited by 24
Self-citationElevated incidence of fractures in women with invasive breast cancer
Edwards, B. J.-A., Gradishar, W., Smith, M. E., Pacheco, J. A., Holbrook, J. S., McKoy, J. M., Nardone, B., Tica, S., Godinez-Puig, V., RADEMAKER, A. W., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3246-3 · Cited by 24
Villa, P., Lassandro, A. P., Amar, I. D., Vacca, L., Moruzzi, M. C., Ferrandina, G., Terribile, D. A., Masetti, R., & Scambia, G. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000515 · Cited by 19
Kyvernitakis, I., Knöll, D., Struck, M. B., Hars, O., Bauer, T., & Hadji, P. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1557-3 · Cited by 18
Self-citationIncreased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
Kim, W., Chung, Y., Kim, S. H., Park, S., Bae, J. H., Kim, G., Lee, S. J., Kim, J. E., Park, B., Lim, S.-K., et al. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.58 · Cited by 17
Inoue, H., Hirano, A., Ogura, K., Hattori, A., Kamimura, M., Okubo, F., Tagawa, H., Sakaguchi, S., Kinoshita, J., & Shimizu, T. (2015) · SpringerPlus · doi:10.1186/s40064-015-1096-2 · Cited by 8
AI-related BMD variation in actual practice conditions: A prospective cohort study
Rodríguez-Sanz, M., Prieto‐Alhambra, D., Servitja, S., García‐Giralt, N., Garrigós, L., Rodríguez‐Morera, J., Albanell, J., Martinez‐García, M., González, I., Díez‐Pérez, A., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0025 · Cited by 8
Cited by
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Self-citationBone health in cancer: ESMO Clinical Practice Guidelines
Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.019 · Cited by 549
Self-citationBone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Self-citation
Metadata
- Authors
- Hadji, P., Aapro, M. S., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J. Y., Zillikens, M. C., Glüer, C.-C., de Villiers, T., Baber, R., Roodman, G. D., Cooper, C., Langdahl, B., Palacios, S., Kanis, J., Al-Daghri, N., Nogues, X., Eriksen, E. F., Kurth, A., Rizzoli, R., & Coleman, R. E.
- Venue
- Journal of Bone Oncology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 7
- Pages
- 1-12
- ISSN
- 2212-1366 (ISSN-L)
- 2212-1374
- OpenAlex
- W2598259575
- Cited by
- 277
- References
- 103
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.